Australia Minimally Invasive Surgery Devices Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia minimally invasive surgery devices market is at an inflection point. Open and basic laparoscopic procedures historically dominated theatre lists, but robotic platforms, day case surgery models and public hospital adoption are now moving minimally invasive techniques into mainstream, higher volume care.

Three forces are shaping the market: the NSW High Volume Short Stay surgery programme; Queensland Surgery Connect, backed by AUD 247 million in the 2026-27 Budget; and the arrival of the da Vinci 5 platform alongside lower cost robotic challengers.

In October 2025, NSW committed AUD 30 million to short stay surgery, and in March 2026 Epworth Freemasons became the first Australian hospital to install the da Vinci 5. In May 2026, Victoria budgeted AUD 27 million for bowel cancer endoscopies.

Key Market Trends and Insights

• Flagship adoption: Epworth Freemasons installed Australia's first da Vinci 5 in March 2026, and Sydney Adventist Hospital completed more than 1,000 da Vinci procedures in 2025, showing how large private centres anchor demand for robotic minimally invasive surgery.
• Platform competition: Concord Hospital began a one year Toumai robot trial in March 2026 with 80 to 100 patients, testing whether lower cost systems and telesurgery can widen public access beyond the da Vinci used at Royal Prince Alfred.
• Public funding: Queensland allocated AUD 247 million to Surgery Connect in the 2026-27 Budget for more than 25,000 additional surgeries, while NSW directed AUD 30 million to short stay units covering hernia, urology and gynaecology cases.
• Regional access: Cairns Hospital is raising AUD 4.3 million for a urology robot expected to operate by the end of 2026, which would let it perform up to 200 urological procedures a year instead of outsourcing about 50.

Australia Minimally Invasive Surgery Devices Market Size and Forecast

The market is moving from open and basic laparoscopic surgery towards platform-based care built on robotics, high definition visualisation and day case pathways. Endoscopic devices lead because every procedure needs a camera, light source and access instruments, while robotic-assisted systems and urology applications grow fastest, with Queensland advancing quickest and New South Wales remaining the largest state.

Key Takeaways: Australia Minimally Invasive Surgery Devices Market

Short Stay Surgery Funding Anchors Long-Term Growth

Revenue is on course to expand by roughly 72% across the decade, from AUD 1,840.78 million in 2025 to AUD 3,174.25 million in 2035 at a 5.6% CAGR. Waiting list pressure and day case care keep demand durable, while the NSW AUD 30 million programme and Queensland Surgery Connect turn that demand into funded theatre capacity.

Robotic Systems Lead New Deployments

Robotic-Assisted Systems are the fastest-growing product type at an estimated 6.6% CAGR through 2035, with Urology the fastest application at 7.0%. Wristed instruments and stable three dimensional vision suit confined anatomy, and Intuitive placed 468 da Vinci systems worldwide in the second quarter of 2026.

Epworth da Vinci 5 Install Signals Acceleration

Epworth Freemasons in Melbourne received Australia's first da Vinci 5 in March 2026, followed by first procedures at Sydney Adventist Hospital in April 2026 and a AUD 4.2 million purchase at Mater Springfield in May 2026. Further installations are expected through the remainder of 2026.

• Over 1,000 da Vinci procedures were completed at Sydney Adventist Hospital in 2025
• Device Technologies supported the Australian rollout of the da Vinci 5
• Installations span East Melbourne, Sydney and Springfield, with six new theatres at Mater

Australia Minimally Invasive Surgery Devices Market Report Summary

Key Insight

Demand is structural, not cyclical. Ageing patients, waiting list pressure and public funding for short stay surgery push hospitals towards smaller incisions, with robotic systems and Queensland growing fastest.

Key Trends in the Australia Minimally Invasive Surgery Devices Market

The Australia minimally invasive surgery devices market is being reshaped by state funded short stay surgery, next generation robotic platforms, and public hospital trials of lower cost systems.

August 2026 - NSW Expands Short Stay Surgery With Statewide Day Case Capacity

• NSW said in August 2026 that its AUD 30 million programme will deliver 2,300 additional surgeries by mid 2027.
• Units at Campbelltown, Shellharbour and Wagga Wagga handle hernia, gynaecology and urology cases with stays of up to 72 hours.
• Laparoscopic and endoscopic device suppliers gain recurring volume as day case lists grow.

May 2026 - Mater Springfield Adds Queensland First da Vinci 5 Robot Through Donations

• Mater Hospital Springfield bought a da Vinci 5 for AUD 4.2 million in May 2026, funded by donations through Mater Foundation.
• It will support urology, gynaecology and general procedures, including cancer surgery, in one of six newly built theatres.
• Philanthropic funding lets not for profit hospitals add robotic capacity ahead of public budgets.

March 2026 - Concord Hospital Trial Tests Lower Cost Robotic Surgery in Public Care

• Concord Hospital performed the first Toumai robot surgery in an Australian public facility in March 2026, starting a one year trial.
• About 80 to 100 patients will be compared with outcomes from the da Vinci system used at Royal Prince Alfred Hospital.
• Telesurgery potential could let metropolitan surgeons operate on rural patients, and lower prices would widen public access.

January 2026 - ARTG Listing Opens Australia to the Next Generation da Vinci 5 Platform

• The da Vinci 5 was entered on the ARTG as number 97348, as announced in January 2026.
• The platform offers four times the pixel resolution and 10,000 times the computing power of its predecessor.
• Hospitals gain a regulated route to upgrade Xi fleets, while distributor Device Technologies gains a platform to place.

Key Insight

Growth is structurally locked in. State surgery funding, next generation robot approvals and public trials of lower cost systems show policy, demand and technology moving together.

Recent Market Developments in the Australia Minimally Invasive Surgery Devices Market

Recent developments, presented from the most recent, show the Australia minimally invasive surgery devices market moving from regulatory clearances into installed capacity and record placements.

July 2026 - Intuitive Surgical Reports 468 da Vinci Placements in Second Quarter

• Intuitive reported 468 da Vinci placements for the second quarter in July 2026, against 395 a year earlier.
• Global da Vinci procedures rose 15% and the installed base reached 11,710 systems, a 12% increase.
• Full year procedure growth is guided at 13.5% to 15.5%, signalling steady platform supply for markets such as Australia.

April 2026 - Sydney Adventist Hospital Completes Southern Hemisphere First da Vinci 5 Procedures

• Sydney Adventist Hospital completed the first da Vinci 5 colorectal procedure in April 2026, followed by the first cardiac case.
• The hospital completed over 1,000 da Vinci procedures in 2025 and hosts the country's highest number of robotic proctors.
• Telesurgery features of the platform could widen specialist access for regional and remote patients.

January 2026 - Johnson & Johnson MedTech Submits OTTAVA Robotic System to the FDA

• Johnson & Johnson submitted OTTAVA to the FDA in January 2026 for De Novo classification in upper abdominal general surgery.
• Indications cover gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair, with a second inguinal hernia trial.
• The system pairs Ethicon instruments with the Polyphonic digital ecosystem, and first cases were completed in early 2025.

December 2025 - Medtronic Wins FDA Clearance for Hugo Robotic System in Urology

• Medtronic received FDA clearance for Hugo in urology in December 2025, after submitting the filing in April 2025.
• The first United States case, a prostatectomy, followed at Cleveland Clinic in February 2026.
• Gynaecology and hernia studies are advancing, with the hernia study meeting its endpoints, to extend Hugo beyond urology.

Key Insight

The sequence shifts from regulation to delivery. New platform clearances widened choice, while da Vinci 5 procedures and record placements show demand converting into installed robotic capacity.

Australia Minimally Invasive Surgery Devices Industry Segmentation

The Expert Market Research’s report on the Australia Minimally Invasive Surgery Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Handheld Instruments
• Endoscopic Devices
• Electrosurgical Devices
• Robotic-Assisted Systems
• Others

Endoscopic Devices lead because laparoscopes, cameras and visualisation towers are needed in nearly every procedure, and Karl Storz acquired the T1V medical business in January 2025 to deepen digital operating room tools. Robotic-Assisted Systems are the fastest-growing product type at an estimated 6.6% CAGR through 2035, with the da Vinci 5 installed at Epworth Freemasons in March 2026. Electrosurgical Devices benefit from advanced energy demand, which Medtronic said grew at high single digits in June 2026. Handheld Instruments such as graspers, staplers and scissors remain the volume base. Others include trocars, insufflators and specimen retrieval devices.

Market Breakup by Application

• General Surgery
• Gynecology
• Orthopedic
• Cardiovascular
• Urology
• Others

General Surgery leads because hernia, colorectal and bariatric cases fill NSW short stay lists, Shellharbour Hospital set up a service in September 2026, and the Northern Beaches Hospital Surgery Hub opened in July 2026 for up to 5,000 surgeries a year. Urology is the fastest-growing application at an estimated 7.0% CAGR through 2035, as Cairns Hospital said in June 2026 that its robot would allow 200 procedures a year. Gynecology gained from the Hugo gynaecology study reported by Medtronic in November 2025, Orthopedic from Mako shoulder surgery at Buderim in August 2025, and Cardiovascular from the first da Vinci 5 cardiac case in April 2026. Others cover thoracic, ENT and paediatric surgery.

Market Breakup by End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Hospitals lead because large private and public sites hold the robot fleets, with Epworth Freemasons installing the da Vinci 5 in March 2026 and Cairns Private Hospital adding a second ROSA knee robot in September 2025. Ambulatory Surgical Centers are the fastest-growing end user at an estimated 7.2% CAGR through 2035, supported by day case models such as Queensland Surgery Connect, which reached 32 contracted providers in July 2026. Specialty Clinics, including endoscopy and urology practices, gain from Victoria's AUD 27 million bowel cancer endoscopy funding announced in May 2026. Others cover small day hospitals outside these three settings.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates at an estimated 5.5% CAGR, anchored by Sydney Adventist Hospital, which began da Vinci 5 procedures in April 2026, and by the Northern Beaches Surgery Hub. Queensland grows fastest at an estimated 6.3%, as The Prince Charles Hospital brought a second surgical robot online in February 2026 and Mater Springfield added a da Vinci 5 in May 2026. Victoria advances at 5.4% on the Epworth Freemasons da Vinci 5, Western Australia at 5.8% and South Australia at 5.3%, where Royal Adelaide Hospital pioneered public robotic surgery. Others grow at 5.1% and include Tasmania, with Launceston General Hospital's surgical robot, the Australian Capital Territory and the Northern Territory.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Minimally Invasive Surgery Devices Market

Competition combines global surgical technology groups, endoscopy specialists and orthopaedic platform owners supplying hospitals, day surgery centres and clinics across Australia. Entry barriers include ARTG registration, surgeon training and proctoring networks, installed robotic bases and multi-year service and consumable contracts.

Medtronic

Medtronic, headquartered in Dublin, Ireland, and founded in 1949, supplies the Hugo robotic-assisted surgery system alongside Covidien LigaSure advanced energy, Signia stapling and laparoscopic access products. Hurstville Private Hospital in Sydney was the first Australian site to offer Hugo, and Medtronic received FDA clearance for Hugo in urology in December 2025, after reporting fiscal 2025 results in May 2025, and reported fiscal 2026 revenue of USD 36.4 billion in June 2026. Its differentiators are a broad energy and stapling installed base and an open console robotic design.

Johnson & Johnson MedTech (Ethicon)

Johnson & Johnson MedTech (Ethicon), headquartered in New Brunswick, New Jersey, supplies Ethicon sutures, Echelon staplers, Harmonic and Enseal energy devices, and the OTTAVA robotic system under review. In Australia, its DePuy Synthes Velys robotic knee was first used at The Mater Hospital Sydney, giving it a robotic orthopaedic footprint, and OTTAVA went to the FDA in January 2026. Its differentiators are surgeon familiarity with Ethicon consumables and a soft tissue robot designed around those instruments.

Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, supplies the da Vinci Xi, da Vinci 5 and da Vinci SP systems and the Ion lung biopsy platform, and reported 180 da Vinci 5 placements for the second quarter of 2025 in July 2025. In Australia, the da Vinci 5 was listed on the ARTG in January 2026 and first installed at Epworth Freemasons in March 2026, with Device Technologies supporting rollout. Its differentiators are the largest installed base, at 11,710 systems in July 2026, and established surgeon training pathways.

Stryker

Stryker, founded in 1941 and headquartered in Kalamazoo, Michigan, supplies the Mako robotic system, endoscopy and visualisation towers, surgical lighting, navigation and orthopaedic implants. In Australia, Buderim Private Hospital introduced Mako robotic shoulder surgery in August 2025, and Stryker completed its Inari Medical acquisition at USD 80 per share in February 2025. Its differentiators are integrated implant and robot ecosystems, and a Mako base that passed 2.5 million procedures across 47 countries by July 2026.

Other players operating in the Australia minimally invasive surgery devices market include Olympus, Boston Scientific, Smith+Nephew, Karl Storz, and Cook Medical, alongside specialist endoscopy, arthroscopy, interventional and electrosurgical suppliers and local distributors supporting visualisation, ureteroscopy, joint repair and day surgery workflows.

Key Insight

Competition rests on platform capability, instrument ecosystems and service coverage rather than price alone. Consolidation, including Boston Scientific's agreed Penumbra acquisition, keeps reshaping the supplier field.